Hostname: page-component-76d6cb85b7-ntvhh Total loading time: 0 Render date: 2026-07-16T14:35:40.096Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of paediatric laryngeal papillomas: web survey of British Association of Paediatric Otolaryngologists

Published online by Cambridge University Press:  08 August 2013

J Manickavasagam ,
K Wu  and
N D Bateman
J Manickavasagam*
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Royal Hallamshire University Hospital & Sheffield Childrens Hospitals, Sheffield, UK
K Wu
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Royal Hallamshire University Hospital & Sheffield Childrens Hospitals, Sheffield, UK
N D Bateman
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Royal Hallamshire University Hospital & Sheffield Childrens Hospitals, Sheffield, UK
*
Address for correspondence: Mr J Manickavasagam, Department of Otorhinolaryngology and Head and Neck Surgery, Royal Hallamshire University Hospital, Sheffield S10 2JF, UK E-mail: jaiganeshkalpana@yahoo.co.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background and objective:

Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children. Intralesional injection of cidofovir may have some potential as an adjunctive treatment. There is no standardised protocol in the UK for the management of recurrent respiratory papillomatosis. This study aimed to investigate the management practices of surgeons treating paediatric recurrent respiratory papillomatosis in the UK.

Method:

A web questionnaire survey was sent by e-mail to all members of the British Association of Paediatric Otorhinolaryngology.

Results:

Out of 35 respondents, 23 were at that time treating children with recurrent respiratory papillomatosis. Nineteen respondents preferred to use a microdebrider, 12 preferred laser, and 5 preferred cold steel along with either laser or a microdebrider. Twelve surgeons used cidofovir for selected patients and 12 surgeons did not use cidofovir for any patients. Cidofovir was considered after 0–4 surgical procedures by seven respondents, after 4–6 surgical procedures by four respondents and after 6 surgical procedures by six respondents. Eleven respondents warned patients about the possible side effects of cidofovir and five gave no warning.

Conclusion:

There was no consensus as to when it would be appropriate to use cidofovir, indicating the need for cidofovir usage guidelines.

Keywords

PediatricLaryngeal PapillomatosisUnited KingdomSurveysTherapyCidofovir

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 9 , September 2013 , pp. 917 - 921
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Presented orally at the 7th Congress of the European Laryngological Society, 29 May 2008, Barcelona, Spain, and at the Annual and Academic Meeting of the British Association for Paediatric Otorhinolaryngology, 12 September 2008, Epsom, UK.

References

1Shehab, N, Sweet, BV, Hogikyan, ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 2005;25:977–89Google Scholar
2Andrews, TM, Myer, CM. Malignant (atypical) carcinoid of the larynx occurring in a patient with laryngotracheal papillomatosis. Am J Otolaryngol 1992;13:238–42Google Scholar
3Doyle, DJ, Henderson, LA, LeJeune, FE Jr, Miller, RH. Changes in human papillomavirus typing of recurrent respiratory papillomatosis progressing to malignant neoplasm. Arch Otolaryngol Head Neck Surg 1994;120:1273–6Google Scholar
4Kimberlin, DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 2004;63:141–51Google Scholar
5Chung, BJ, Akst, LM, Koltai, PJ. 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2006;70:1911–17Google Scholar
6Donne, AJ, Hampson, L, He, XT, Day, PJR, Salway, F, Rothera, MP et al. Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antivir Ther 2009;14:939–52Google Scholar
7Vistide - Patient Information Leaflet (PIL). In: http://www.medicines.org.uk/EMC/medicine/3629/PIL/Vistide/ [23 June 2012]Google Scholar
8Soma, MA, Albert, DM. Cidofovir: to use or not to use? Curr Opin Otolaryngol Head Neck Surg 2008;16:86–90Google Scholar
9Naiman, AN, Ayari, S, Nicollas, R, Landry, G, Colombeau, B, Froehlich, P. Intermediate-term and long-term results after treatment by cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 2006;115:667–72Google Scholar
10Chadha, NK, James, AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg 2007;136:863–9Google Scholar
11Dikkers, FG. Intralesional cidofovir does not increase the risk of laryngeal dysplasia or laryngeal carcinoma. Int J Pediatr Otorhinolaryngol 2008;72:1581–2Google Scholar
12Donne, AJ, Rothera, MP, Homer, JJ. Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2008;72:939–44Google Scholar
13Wemer, RD, Lee, JH, Hoffman, HT, Robinson, RA, Smith, RJ. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005;114:836–9Google Scholar
14Inglis, AF Jr. Cidofovir and the black box warning. Ann Otol Rhinol Laryngol 2005;114:834–5Google Scholar
15Tjon Pian Gi, RE, Dietz, A, Djukic, V, Eckel, HE, Friedrich, G, Golusinski, W et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®). Eur Arch Otorhinolaryngol 2012;269:361–2Google Scholar
16Direct healthcare professional communication regarding serious adverse reactions following off-label use of Vistide. In: http://www.cbg-meb.nl/NR/rdonlyres/FFB51936-EC22-4180-A213-9E907F06A774/0/VistideDHPCletterJanuary2011.pdf [12 January 2012]Google Scholar
17Schraff, S, Derkay, CS, Burke, B, Lawson, L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039–42Google Scholar